Natural History of Multiple Sclerosis: Early Prognostic Factors

Neurologic Clinics

Volumn 29, Issue 2, 2011, Pages 279-292

  Mowry, Ellen M ^a  

^a UCSF Multiple Sclerosis Center   (United States)

Author keywords

Disability; Multiple sclerosis; Natural history; Prognostic factors; Relapses; Severity

Indexed keywords

GADOLINIUM;

CEREBROSPINAL FLUID ANALYSIS; CONTRAST ENHANCEMENT; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; EVOKED RESPONSE; FOLLOW UP; HUMAN; MULTIPLE SCLEROSIS; NEUROIMAGING; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROGNOSIS; RADIODIAGNOSIS; RELAPSE; REVIEW; RISK ASSESSMENT; UNIVARIATE ANALYSIS;

DISABILITY EVALUATION; DISEASE PROGRESSION; ENVIRONMENT; HUMANS; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS; PREDICTIVE VALUE OF TESTS; PROGNOSIS;

EID: 79952850629     PISSN: 07338619     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ncl.2011.01.001     Document Type: Review

References (78)

1. Gilbert J.J., Sadler M. Unsuspected multiple sclerosis. Arch Neurol 1983, 40:533-536.
2. Phadke J.G., Best P.V. Atypical and clinically silent multiple sclerosis: a report of 12 cases discovered unexpectedly at autopsy. J Neurol Neurosurg Psychiatry 1983, 46:414-420.
3. Okuda D.T., Mowry E.M., Beheshtian A., et al. Incidental MRI anomalies suggestive of multiple sclerosis: the radiologically isolated syndrome. Neurology 2009, 72:800-805.
4. Barkhof F., Filippi M., Miller D.H., et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 1997, 120:2059-2069.
5. Lebrun C., Bensa C., Debouverie M., et al. Unexpected multiple sclerosis: follow-up of 30 patients with magnetic resonance imaging and clinical conversion profile. J Neurol Neurosurg Psychiatry 2008, 79:195-198.
6. Lebrun C., Bensa C., Debouverie M., et al. Association between clinical conversion to multiple sclerosis in radiologically isolated syndrome and magnetic resonance imaging, cerebrospinal fluid, and visual evoked potential: follow-up of 70 patients. Arch Neurol 2009, 66:841-846.
7. Kappos L., Polman C.H., Freedman M.S., et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006, 67:1242-1249.
8. Jacobs L.D., Beck R.W., Simon J.H., et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med 2000, 343:898-904.
9. Comi G., Filippi M., Barkhof F., et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001, 357:1576-1582.
10. Comi G., Martinelli V., Rodegher M., et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomized, double-blind, placebo-controlled trial. Lancet 2009, 374:1503-1511.
11. Frohman E., Havrdova E., Lublin F., et al. Most patients with multiple sclerosis or clinically isolated demyelinating syndrome should be treated at the time of diagnosis. Arch Neurol 2006, 63:614-619.
12. Achiron A., Borak Y. Multiple sclerosis-from probable to definite diagnosis. Arch Neurol 2000, 57:974-979.
13. West T., Wyatt M., High A., et al. Are initial demyelinating event recovery and time to second event under differential control?. Neurology 2006, 67:809-813.
14. Mowry E.M., Pesic M., Grimes B., et al. Clinical predictors of early second event in patients with clinically isolated syndrome. J Neurol 2009, 256:1061-1066.
15. Tintore M., Rovira A., Martinez M.J., et al. Isolated demyelinating syndromes: comparison of different MR imaging criteria to predict conversion to clinically definite multiple sclerosis. AJNR Am J Neuroradiol 2000, 21:702-706.
16. Masjuan J., Alvarez-Cermeno J.C., Garcia-Barragan N., et al. Clinically isolated syndromes: a new oligoclonal band test accurately predicts conversion to MS. Neurology 2006, 28:576-578.
17. Tintore M., Rovira A., Rio J., et al. Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis?. Neurology 2008, 70:1079-1083.
18. Moraal B., Pohl C., Uitdehaag M.B., et al. Magnetic resonance imaging predictors of conversion to multiple sclerosis in the BENEFIT study. Arch Neurol 2009, 66:1345-1352.
19. Tintore M., Rovira A., Rio J. Baseline MRI predicts future attacks and disability in clinically isolated syndromes. Neurology 2006, 67:968-972.
20. CHAMPS Study Group MRI predictors of early conversion to clinically definite MS in the CHAMPS placebo group. Neurology 2002, 59:998-1005.
21. Barkhof F., Rocca M., Francis G., et al. Validation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon β1a. Ann Neurol 2003, 53:718-724.
22. Korteweg T., Tintore M., Uitdehaag B., et al. MRI criteria for dissemination in space in patients with clinically isolated syndromes: a multicentre follow-up study. Lancet Neurol 2006, 5:221-227.
23. DiFilippo M., Andersonn V.M., Altmann D.R., et al. Brain atrophy and lesion load measures over 1 year relate to clinical status after 6 years in patients with clinically isolated syndromes. J Neurol Neurosurg Psychiatry 2010, 81:204-208.
24. Brex P.A., O'Riordan J.I., Miszkiel K.A., et al. Multisequence MRI in clinically isolated syndromes and the early development of MS. Neurology 1999, 53:1184-1190.
25. McDonald W.I., Compston A., Edan G., et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001, 50:121-127.
26. Polman C.H., Reingold S.C., Edan G., et al. Diagnostic revisions for multiple sclerosis: 2005 revisions to the " McDonald Criteria." Ann Neurol 2005, 58:840-846.
27. Swanton J.K., Rovira A., Tintore M., et al. MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: a multicentre retrospective study. Lancet Neurol 2007, 6:677-686.
28. Swanton J.K., Fernando K.T., Dalton C.M., et al. Modification of MRI criteria for multiple sclerosis in patients with clinically isolated syndromes. J Neurol Neurosurg Psychiatry 2006, 77:830-833.
29. Rovira A., Swanton J., Tintore M., et al. A single, early magnetic resonance imaging study in the diagnosis of multiple sclerosis. Arch Neurol 2009, 66:587-592.
30. Polman C.H., Reingold S.C., Banwell B., et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the " McDonald criteria" Ann Neurol 2011, 10.1002/ana.22366.
31. Pelayo R., Montalban X., Minoves T., et al. Do multimodal evoked potentials add information to MRI in clinically isolated syndrome?. Mult Scler 2010, 16:55-61.
32. Brettschneider J., Petzold A., Junker A., et al. Axonal damage markers in the cerebrospinal fluid of patients with clinically isolated syndrome improve predicting conversion to definite multiple sclerosis. Mult Scler 2006, 12:143-148.
33. Comabella M., Fernandez M., Martin R., et al. Cerebrospinal fluid chitinase 3-like levels are associated with conversion to multiple sclerosis. Brain 2010, 133:1082-1093.
34. Corvol J.C., Pelletier D., Henry R.G., et al. Abrogation of T cell quiescence characterizes patients at high risk for multiple sclerosis after the initial neurological event. Proc Natl Acad Sci U S A 2008, 105:11839-11844.
35. Kelly M.A., Cavan D.A., Penny M.A., et al. The influence of HLA-DR and -DQ alleles on progression to multiple sclerosis following a clinically isolated syndrome. Hum Immunol 1993, 37:187-191.
36. DiPauli F., Reindl M., Ehling R., et al. Smoking is a risk factor for early conversion to clinically definite multiple sclerosis. Mult Scler 2008, 14:1026-1030.
37. Lunemann J.D., Tintore M., Messmer B., et al. Elevated Epstein-Barr virus-encoded nuclear antigen-1 immune responses predict conversion to multiple sclerosis. Ann Neurol 2010, 67:159-169.
38. Mowry E.M., Pesic M., Grimes B., et al. Demyelinating events in early multiple sclerosis have inherent severity and recovery. Neurology 2009, 72:602-608.
39. Cree B.A., Khan O., Bourdette D., et al. Clinical characteristics of African Americans vs Caucasian Americans with multiple sclerosis. Neurology 2004, 63:2039-2045.
40. Mowry E.M., Deen S., Malikova I., et al. The onset location of multiple sclerosis predicts the location of subsequent relapses. J Neurol Neurosurg Psychiatry 2009, 80:400-403.
41. Mowry E.M., Krupp L.B., Milazzo M., et al. Vitamin D status is associated with relapse rate in pediatric-onset multiple sclerosis. Ann Neurol 2010, 67:618-624.
42. Tremlett H., Yousefi M., Devonshire V., et al. Impact of multiple sclerosis relapses on progression diminishes with time. Neurology 2009, 73:1616-1623.
43. Mikaeloff Y., Caridade G., Assi S., et al. Prognostic factors for early severity in a childhood multiple sclerosis cohort. Pediatrics 2006, 118:1133-1139.
44. Runmarker B., Andersen O. Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up. Brain 1993, 116:117-134.
45. Amato M.P., Ponziani G. A prospective study on the prognosis of multiple sclerosis. Neurol Sci 2000, 21:S831-S838.
46. Leray E., Yaouanq J., LePage E., et al. Evidence for a two-stage disability progression in multiple sclerosis. Brain 2010, 133(Pt 7):1900-1913.
47. Naismith R.T., Trinkaus K., Cross A.K. Phenotype and prognosis in African-Americans with multiple sclerosis: a retrospective chart review. Mult Scler 2006, 12:775-781.
48. Molyneux P.D., Filippi M., Barkhof F., et al. Correlations between monthly enhanced MRI lesion rate and changes in T2 lesion volume in multiple sclerosis. Ann Neurol 1998, 43:332-339.
49. Kappos L., Moeri D., Radue E.W., et al. Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI Meta-analysis Group. Lancet 1999, 353:964-969.
50. Brex P.A., Ciccarelli O., O'Riordan J.I., et al. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med 2002, 346:158-164.
51. Swanton J.K., Fernando K.T., Miszkiel K.A., et al. Early MRI in optic neuritis. Neurology 2009, 72:542-550.
52. Simpson S., Taylor B., Blizzard L., et al. Higher 25-hydroxyvitamin D is associated with lower relapse risk in MS. Ann Neurol 2010, 68:193-203.
53. Hernan M., Jick S.S., Logroscino G., et al. Cigarette smoking and the progression of multiple sclerosis. Brain 2005, 128:1461-1465.
54. Goodin D.S., Ebers G.C., Johnson K.P., et al. The relationship of MS to physical trauma and psychological stress. Neurology 1999, 52:1737-1745.
55. Confavreux C., Hutchinson M., Hours M.M., et al. Rate of pregnancy-related relapse in multiple sclerosis. N Engl J Med 1998, 339:285-291.
56. Tremlett H., van der Mai I.A., Pittas F., et al. Monthly ambient sunlight, infections and relapse rates in multiple sclerosis. Neuroepidemiology 2008, 31:271-279.
57. Edwards S., Zvartau M., Clarke H., et al. Clinical relapses and disease activity on magnetic resonance imaging associated with viral upper respiratory tract infections in multiple sclerosis. J Neurol Neurosurg Psychiatry 1998, 64:736-741.
58. Buljevac D., Flach H.Z., Hop W.C., et al. Prospective study on the relationship between infections and multiple sclerosis exacerbations. Brain 2002, 125:952-960.
59. Miller A.E., Morgante L.A., Buchwald L.Y., et al. A multicenter, randomized, double-blind, placebo-controlled trial of influenza immunization in multiple sclerosis. Neurology 1997, 48:312-314.
60. Confavreux C., Suissa S., Saddier P., et al. Vaccinations and the risk of relapse in multiple sclerosis. N Engl J Med 2001, 344:319-326.
61. Okuda D.T., Srinivasan R., Oksenberg J.R., et al. Genotype-phenotype correlations in multiple sclerosis: HLA genes influence disease severity inferred by 1HMR spectroscopy and MRI measures. Brain 2009, 132:250-259.
62. Barcellos L.F., Oksenberg J.R., Begovich A.B., et al. HLA-DR2 dose effect on susceptibility to multiple sclerosis and influence on disease course. Am J Hum Genet 2003, 72:710-716.
63. Sedano M.J., Calmarza P., Perez L., et al. No association of apolipoprotein E E4 genotype with faster progression or less recovery of relapses in a Spanish cohort of multiple sclerosis. Mult Scler 2006, 12:13-18.
64. Chapman J., Sylantiev C., Nisipeanu P., et al. Preliminary observations on APOE epsilon4 allele and progression of disability in multiple sclerosis. Arch Neurol 1999, 56:1484-1487.
65. Ramagopalan S.V., DeLuca G.C., Degenhardt A., et al. The genetics of clinical outcome in multiple sclerosis. J Neuroimmunol 2008, 201(202):183-199.
66. The IFNB Multiple Sclerosis Study Group Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993, 43:655-661.
67. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon β-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 1998, 352:1498-1504.
68. Johnson K.P., Brooks B.R., Cohen J.A., et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 1995, 45:1268-1276.
69. Polman C.H., O'Connor P.W., Havrdova E., et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006, 354:899-910.
70. Rudick R.A., Stuart W.H., Calabresi P.A., et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006, 354:911-923.
71. Hartung H.P., Gonsette R., Konig N., et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002, 360:2018-2025.
72. Ramsaransing G.S., DeKeyser J. Predictive value of clinical characteristics for " benign" multiple sclerosis. Eur J Neurol 2007, 14:885-889.
73. Phadke J.G. Clinical aspects of multiple sclerosis in north-east Scotland with particular reference to its course and prognosis. Brain 1990, 113:1597-1628.
74. Weinshenker B.G., Bass B., Rice G.P., et al. The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course. Brain 1989, 112:1419-1428.
75. Confavreux C., Vukusic S., Adeleine P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain 2003, 126:770-782.
76. Binquet C., Quantin C., Le Teuff G., et al. The prognostic value of initial relapses on the evolution of disability in patients with relapsing-remitting multiple sclerosis. Neuroepidemiology 2006, 27:45-54.
77. Langer-Gould A., Popat R.A., Huang S.M., et al. Clinical and demographic predictors of long-term disability in patients with relapsing-remitting multiple sclerosis. Arch Neurol 2006, 63:1686-1691.
78. Koch M., Kingwell E., Rieckmann P., et al. The natural history of primary progressive multiple sclerosis. Neurology 2009, 73:1996-2002.